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Abstract
Background: The naturally occurring benzoquinone ansamycin compound, geldanamycin (GA), is
a specific inhibitor of heat shock protein 90 (Hsp90) and is a potential anticancer agent. Since
Plasmodium falciparum has been reported to have an Hsp90 ortholog, we tested the possibility that
GA might inhibit it and thereby display antiparasitic activity.
Results: We provide direct recombinant DNA evidence for the Hsp90 protein of Plasmodium
falciparum, the causative agent of fatal malaria. While the mRNA of Hsp90 was mainly expressed in
ring and trophozoite stages, the protein was found in all stages, although schizonts contained
relatively lower amounts. In vitro the parasitic Hsp90 exhibited an ATP-binding activity that could
be specifically inhibited by GA. Plasmodium growth in human erythrocyte culture was strongly
inhibited by GA with an IC50 of 20 nM, compared to the IC50 of 15 nM for chloroquine (CQ) under
identical conditions. When used in combination, the two drugs acted synergistically. GA was
equally effective against CQ-sensitive and CQ-resistant strains (3D7 and W2, respectively) and on
all erythrocytic stages of the parasite.
Conclusions: Together, these results suggest that an active and essential Hsp90 chaperone cycle
exists in Plasmodium and that the ansamycin antibiotics will be an important tool to dissect its role
in the parasite. Additionally, the favorable pharmacology of GA, reported in human trials, makes it
a promising antimalarial drug.
Background
As the causative agent of malaria, Plasmodium sp. claims
between one and two million human lives annually
worldwide.  Plasmodium falciparum is particularly lethal
and causes cerebral malaria [1]. A major area in malaria
research is, therefore, focused on finding a potent and reli-
able anti-parasitic drug that would inhibit Plasmodium
infection and growth. In nearly all the malaria-endemic
populations, Plasmodium has developed resistance against
the hallmark drug chloroquine and its derivatives [2–4]. It
is thus appreciated that the new generation of drugs
should use a rational strategy based on the structure and
function of essential parasitic molecules. With this goal
we have concentrated on understanding the signaling
pathways of P. falciparum with special emphasis on pro-
tein phosphorylation. We and others have recently shown
that  P. falciparum contains a PP5 protein phosphatase
containing a tetratricopeptide (TPR) domain [5,6]. We
also showed that PfPP5 interacts with a 90 kDa protein of
the parasite that is antigenically similar to mammalian
heat shock protein 90 (Hsp90) [5]. Because of the enor-
mous importance of PP5 and Hsp90 in cellular
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physiology and signaling [7–9], further studies of both
Plasmodium proteins were warranted.
Hsp90 is the most abundant chaperone in cells and plays
an essential role in the folding, and hence functioning, of
a large number of proteins, especially those participating
in cell cycle regulation and signal transduction [8,9]. The
list of the "client" proteins of Hsp90 is impressively long,
and includes protein kinases such as Raf, Src, Lck, Wee1,
MEK, Cdk4, Src, and CK2, and transcription factors such
as steroid receptors and p53 [8,9]. Because of this, Hsp90
has been used as a drug target in basic as well as clinical
applications [10–15]. Recent studies have revealed a
number of structural and functional aspects of Hsp90 that
include the N-terminal ATP-binding domain and a
sophisticated ATP-dependent conformational change in
the protein [16–19]. At least two natural antibiotics –
geldanamycin (GA) and radicicol – have been experimen-
tally demonstrated to compete with ATP for binding to
the N-terminal domain [16–20]. GA, in particular, is con-
sidered a highly specific inhibitor of Hsp90 and its deriv-
ative, 17-(allylamino)-17-Demethoxygeldanamycin
(17AAG), is in Phase I trials as an antitumor agent [12–
15]. Inhibition of Hsp90 by these antibiotics and others
abolish Hsp90-dependent folding of immature client pro-
teins and direct them to ubiquitin-mediated proteolytic
degradation [21,22]. The gene and cDNA sequence of
PfHsp90 have been characterized, and the deduced pro-
tein sequence revealed its obvious similarity to Hsp90
from other species and its high conservation among P. fal-
ciparum isolates [23,24]. The cDNA sequence was consid-
ered to correspond to this protein since a monoclonal
antibody that reacted with the 90 kDa antigen was used to
screen the cDNA library. Furthermore, the same antibody
reacted with a 90 kDa Plasmodium protein that bound to
ATP-agarose [23,25]. Sera of humans, mice, and squirrel
monkeys, exposed to Plasmodium,  contained abundant
amounts of antibody reactive to the 90 kDa protein [25–
27], suggesting that it may have a major antigenic role in
malaria.
Based on the foregoing, we conjectured that PfHsp90
might play a critical role in parasitic signaling and cell
division, and by corollary, GA might inhibit P. falciparum
growth. In this communication, we show that this is true
and present detailed studies of the effect of GA on P. falci-
parum replication and morphology. Our evidence suggests
that GA inhibits the ATP-binding activity of PfHsp90. This
is likely to inhibit the Hsp90 chaperone cycle, thus pro-
viding a working hypothesis for the antiparasitic activity
of GA.
Materials and Methods
Antibodies, reagents, parasite culture, and drug treatment
Monoclonal mouse antibody against Achlya Hsp90 was
purchased from Sigma, and was found to react with
PfHsp90 [5]. Antibody to the T7-tag peptide was from
Novagen (EMD Biosciences, Inc., Madison, WI, USA).
Chloroquine (CQ) was purchased from Sigma, and [8-
3H]-hypoxanthine, from Perkin Elmer. Geldanamycin
was provided by NCI, and its stock solution and appropri-
ate dilutions were made in DMSO.
P. falciparum (3D7 or W2) was grown on A-positive
human erythrocytes at 5% hematocrit in the presence of
homologous serum as described earlier [28]. The parasite
morphology and stage-specific development were evalu-
ated by microscopic inspection of Giemsa-stained thin
smears [29]. To determine parasitemia, about 500 eryth-
rocytes were examined and the number of infected eryth-
rocytes was reported as percentage of the total. Stage-
specific development was assessed by examining a mini-
mum of 400 parasitized cells on each smear for differen-
tial counting of rings, trophozoites, schizonts, and
pyknotic forms whose exact morphology could not be
established. The fraction of each group was calculated as a
percentage of the total number of parasitized cells.
When needed, the cultures were synchronized to ring
stage by D-sorbitol treatment as described earlier [28,30].
Four hours post-sorbitol treatment was taken as 0 h, and
synchronized parasites were collected (or treated with
drug) at various times afterwards, as described in the
respective Figure legends. The different morphogenetic
stages were timed as follows: early trophozoite (20 h); late
trophozoite (26 h); early schizont (32 h); late schizont
(40 h); ring (48 h). Synchrony persisted well through two
cycles; the purity of individual stages was confirmed to be
greater than 95% by light microscopic examination of the
Geimsa-stained thin smears of the cultures [29].
Asynchronous or ring-stage synchronized culture at 4 h
after sorbitol treatment was seeded in 12-well culture
plates. When needed, the cultures were treated with the
drugs (or DMSO control for GA and sterile de-ionized
water control for CQ) for different time intervals as indi-
cated in the figure legends. The 3H-hypoxanthine incorpo-
ration was carried out as described earlier [31] with minor
modifications. All incorporations were measured in tripli-
cate, and the average presented.
Cloning and expression of recombinant PfHsp90 cDNA
The cDNA of P. falciparum Hsp90 (PfHsp90) was first
amplified by reverse transcriptase-PCR using the follow-
ing primers based on the published sequence [23,24]:
ATGTCAACGGAAACATTCGCATTTAAC (sense), and
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(A) Native and recombinant expression of PfHsp90: E. coli BL21(DE3) containing pMICO plasmid [32] and either the pET23a- PfHsp90 clone (lane C) or just the pET-23a vector (no insert) (lane V) were induced with IPTG, analyzed in SDS-PAGE, fol- lowed by staining Figure 1
(A) Native and recombinant expression of PfHsp90: E. coli BL21(DE3) containing pMICO plasmid [32] and either the pET23a-
PfHsp90 clone (lane C) or just the pET-23a vector (no insert) (lane V) were induced with IPTG, analyzed in SDS-PAGE, fol-
lowed by staining. Proteins from duplicate gels were probed in immunoblot with antibody against T7-tag or Hsp90 (Sigma), as 
described under Materials and Methods. In the far right panel, 50 µg of total parasitic protein was similarly analyzed, and 
probed with the same anti-Hsp90 antibody. The roughly 92 k His-tagged recombinant and 90 k parasitic Hsp90 bands are indi-
cated by arrowheads (left and right, respectively); Mr values (in thousands) of protein markers are shown on the left. (B) Stage-
specific expression of Hsp90 mRNA in the parasite: Parasites were synchronized by sorbitol treatment and harvested at time 
points corresponding to the following stages: 20 h (early trophozoite), 26 h (late trophozoite), 32 h (early schizont), 40 h (late 
schizont), 48 h (ring, from the second cycle of synchrony). The upper panel shows a Northern of the total parasitic RNA 
probed with 32P-labeled PCR product corresponding to nucleotide 450–990 of Hsp90 ORF. The 2.9 kb Hsp90 mRNA is so 
indicated. The lower panel is an ethidium bromide stained picture of the parental gel, showing the ribosomal RNAs and size 
markers (lane M). (C) Agreement of Northern data with microarray analysis [34]. The intensities of the PfHsp90 mRNA bands 
(panel B) were quantified by densitometry, normalized against rRNA, and plotted as green bars of relative height. The bars 
were superimposed on the DeRisi microarray data for Hsp90 mRNA throughout the intraerythrocytic cycle [34]. (D) Stage-
specific expression of the Hsp90 protein: Immunoblot of 30 µg of total protein from the same parasitic stages as in panel (B). 
The Immunoblot for PfARP protein, which is constitutively expressed in all stages [35], serves as control for sample loading.
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start codon ATG and the antisense stop codon TTA are
underlined). The 2238 bp long product was further ampli-
fied with similar primers that additionally contained Bam
HI and Xho I restriction sites, respectively, and the result-
ant final product cloned in the corresponding sites of pET-
23a (Novagen), such that the recombinant protein would
have a T7-tag at the N-terminus. The clone was confirmed
by dideoxy sequencing using the ABI Big Dye terminator
technology and introduced into E. coli BL21(DE3) con-
taining the pMICO plasmid [32]. The resultant strain,
upon induction with IPTG, produced the expected 92,000
Mr recombinant protein (Fig. 1).
Interaction of PfHsp90 with ATP and GA
Hsp90-binding to ATP-Sepharose column (Upstate Bio-
technology, Inc., Lake Placid, NY) was tested essentially as
described [19,23]. Saponin-purified parasite pellets were
resuspended in an appropriate volume of buffer A (50
mM Tris-Cl, pH 7.8, 50 mM NaCl, 1 mM DTT, 0.01%
Nonidet P-40, 15 mM Na2MoO4, 2 mM MgCl2, 5 mM
MnCl2), and lysed by pipetting and sonication. The lysate
was clarified by centrifugation at 15,000 × g for 20 min in
a refrigerated centrifuge. Each reaction sample was pre-
pared by mixing 80 µg (by protein assay) of the P. falci-
parum  lysate with 25 µl of ATP-Sepharose in a total
volume of 250 µl. As and where mentioned (Fig. 2), addi-
tions or subtractions (e.g., GA, nucleotides etc.) were
made to the Plasmodium extract prior to its addition to the
resin. After incubation at 30°C for 20 min (with mixing
on a rotating shaker to prevent the settling of the resin),
the resins were washed 4 times with ice-cold buffer A, and
the bound Hsp90 was extracted by boiling in 1× Laemmli
sample buffer [33] and analyzed by SDS-PAGE followed
by immunoblot (Western) using the Super Signal Ultra
chemiluminescence procedure (Pierce, Rockford, IL) as
described [5]. In the control experiment, ovalbumin (20
µg), which has no ATP-binding activity, was used instead
of the Plasmodium lysate.
Results
Characterization of Pf Hsp90 cDNA and stage-specific 
expression of the protein
To obtain direct evidence for the identity of PfHsp90 and
to initiate studies of its biochemistry, we cloned its cDNA
and expressed the recombinant protein in bacteria.
Results (Fig. 1) show that the T7-tagged recombinant pro-
tein reacts with anti-T7 tag as well as human Hsp90 anti-
bodies, thus confirming the cDNA sequence. The
observed Mr of the protein (about 92 k) is in agreement
with the predicted molecular weight of PfHsp90 (86.2
kDa) plus approximately 2 kDa for the T7-tag. The protein
also has a predicted acidic pI of 4.94 http://us.expasy.org/
tools/pi_tool.html, which should retard its mobility on
SDS-PAGE. The stage-specific expression pattern of the
Hsp90 mRNA (Fig. 1B) confirmed previous findings [23]
that the mRNA is abundant in the ring and early tropho-
zoite stages, but extremely low in schizont, indicating
potential regulation at the level of transcription or mRNA
stability. Our data closely matched the recent results of
Bozdech et al [34] obtained by microarray analysis of the
PfHsp90 transcript throughout the intraerythrocytic
developmental cycle (Fig. 1C). Measurement of Hsp90
protein by immunoblot analysis (Fig. 1D) revealed
Interaction of PfHsp90 with ATP and GA Figure 2
Interaction of PfHsp90 with ATP and GA. PfHsp90 was 
allowed to bind to ATP-Sepharose [19] as described under 
Materials and Methods, with the following additions to the 
incubation mixture (Panel A): None (lane 1), 10 µg/ml GA 
(lane 2), 10 mM ATP (lane 3), 20 mM EDTA (lane 4), 10 mM 
GTP (lane 5). Lane 0 shows the input amount. The bound 
Hsp90 was analyzed by SDS-PAGE and Western as described 
under Materials and Methods. Panel A shows a representa-
tive immunoblot. Similar experiments were also performed 
with various concentrations of ADP, ATP, and GTP, and the 
amounts of Hsp90 bound to ATP-Sepharose were deter-
mined from densitometric scan of the blot and plotted in 
Panel B.
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comparable amounts in all stages except the late schizont,
where only low amounts are present. Comparing the RNA
and protein levels we conjecture that Hsp90 is translated
mainly in the ring and trophozoite stages; however, it is a
relatively stable protein that continues to persist through
much of the schizont stage, starting to disappear only in
the late schizonts.
Interaction of PfHsp90 with ATP and GA
Crystallographic as well as biochemical studies have doc-
umented that Hsp90 possesses an ATP-binding activity,
and that GA, by virtue of its structural similarity to ATP
competes for binding to the N-terminal ATP-binding
pocket [8,16,17,19,20]. In vitro, purified Hsp90 was
shown to bind to immobilized ATP linked to the matrix
via the γ-phosphate, and this could be abolished by pre-
incubation of the Hsp90 with GA [19]. Binding was also
inhibited by free ATP and ADP, but not by GTP. Since the
biochemistry of parasitic Hsp90 has not been studied, we
carried out preliminary experiments in an attempt to
understand GA action. As described under Discussion,
p23 is a co-chaperone important to the function of
Hsp90, and previous work showed that the formation of
the p23-Hsp90 complex requires ATP and Mg+2 [36,37].
We have, therefore, adopted similar conditions for bind-
ing of native parasitic Hsp90 to ATP-Sepharose. As shown
in Fig. 2, upon incubation of P. falciparum extracts with
ATP-Sepharose, PfHsp90 was indeed detected in the
bound material by immunoblot assay. In the control
experiment, ovalbumin did not bind to the column [19],
demonstrating specificity of binding (data not shown).
The association of PfHsp90 was abolished in the presence
of EDTA, confirming a role of divalent cations [23]. ATP
and ADP also inhibited binding in a concentration-
dependent manner whereas GTP failed to do so.
Antimalarial effect of GA is independent of CQ-resistance
The original antimalarial drug, chloroquine (CQ), serves
as the hallmark against which new antimalarials are gen-
erally compared. In different CQ-sensitive strains, the IC50
(i.e., concentration of the drug that causes 50% inhibi-
tion) has been reported to range from approximately 10
to 50 nM [38,39]. In our in vitro culture, when CQ and GA
were compared against P. falciparum strain 3D7 under
identical conditions, the IC50 of CQ was about 12 nM,
whereas that of GA was about 20 nM (Fig. 3). Thus, it
appears that GA is about half as potent as CQ.
Since CQ-resistance is a major problem in malaria ther-
apy, and multi-drug resistance is a common phenomenon
in Plasmodium and other parasites [4,40], we tested if CQ-
resistant parasites were simultaneously GA-resistant. Fig.
3 shows that GA is equally effective against the CQ-sensi-
tive strain 3D7 and the CQ-resistant strain W2.
Geldanamycin and chloroquine are synergistic inhibitors of 
Plasmodium growth
In principle, two antimalarials can interact in a variety of
ways: they may have no effect on each other, or they may
facilitate or antagonize each other [4,38,39]. For example,
the antimalarial effect of clotrimazole (IC50 = 1 µM) is
antagonized by CQ, but is synergistic to that of meflo-
quine [41]. Therefore, we tested how the antimalarial
activity of GA interacts with that of CQ, a commonly used
antimalarial. Various ratios of the two drugs were used
over a range of concentrations spanning their individual
IC50 values, as described under Materials and Methods.
The isobologram (Fig. 4) shows a concave curve, suggest-
ing a synergistic interaction between CQ and GA in inhib-
iting parasite growth.
GA-mediated inhibition is rapid
To determine if the GA effect occurs in the same stage or if
it is delayed, the morphological parasitemia (defined
under Materials and Methods) was followed for short as
well as long periods following GA addition to the culture.
As shown in Fig. 5, the inhibitory effect on the rate of
increase of parasitemia was immediately discernible start-
ing at a GA concentration between 10–20 nM, which
approximated the IC50 value determined by DNA synthe-
sis inhibition assay (i.e., hypoxanthine incorporation). At
Inhibition of CQ-sensitive (3D7) and CQ-resistant (W2) P.  falciparum by GA Figure 3
Inhibition of CQ-sensitive (3D7) and CQ-resistant (W2) P. 
falciparum by GA. Asynchronous cultures at 5% parasitemia 
were incubated with varying concentrations of GA or CQ, 
3H-hypoxanthine incorporation was measured as described 
under Materials and Methods, and the incorporation was 
expressed as percentage of untreated samples.
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GA concentrations of four times the IC50 (80 nM) and
higher, parasitemia never increased with time, and actu-
ally decreased below the initial number, suggesting that
either the parasites or the infected RBCs were destroyed
when the GA effect was severe. These results suggest that
GA-mediated inhibition is manifested within a single cell
cycle, and is thus, likely to be a relatively rapid effect.
GA causes death and disintegration of all parasitic stages
A series of experiments was next carried out to determine
whether all the stages of the parasitic life cycle were
directly affected by GA. A range of GA concentrations (10
to 100 nM) were first tested on P. falciparum-infected RBC,
and growth of the parasite was measured by staining. In
an asynchronous culture that contained the three major
Plasmodium life stages (ring, trophozoite, and schizont),
all became morphologically abnormal (Fig. 6) and later
disappeared from the culture, confirming the results from
Fig. 5.
To directly examine how GA affects the progression of the
parasitic life cycle, a synchronous culture starting with
early ring stage was exposed to a range of GA concentra-
tions (spanning both sides of the IC50) and parasites were
checked at 24 h and 48 h. As shown in Fig. 7, all rings in
the control untreated (0 nM GA) culture advanced to
trophozoite in 24 h, as expected [34]. In contrast, with
increasing GA concentrations, progressively more and
more parasites failed to make it to trophozoite, and
instead shrank to pyknotic masses. After 48 h exposure to
GA, some of these trophozoites made it to ring in the sec-
ond cycle, but the remainder turned to pyknotic masses
(Fig. 7). At GA concentrations of 40 nM and higher essen-
tially all rings turned pyknotic after 48 h. Taken together,
these results show that GA inhibits all intraerythrocytic
Synergistic antimalarial activity of GA and CQ Figure 4
Synergistic antimalarial activity of GA and CQ. Erythrocytic P. 
falciparum 3D7 cultures at about 5% parasitemia were 
treated with combinatorial concentrations of GA and CQ, 
and the incorporation of 3H-hypoxanthine was measured as 
described in Material and Methods. The concentration of 
each drug was expressed as fraction of its IC50 when used 
alone, and an isobologram was plotted essentially as 
described [37]. In such plots, a concave graph reflects syner-
gism, a straight line reflects additive effect, and a convex 
graph reflects antagonism between two drugs [37]. A hypo-
thetical straight line (broken) is drawn here for comparison, 
whereas the experimental graph, which is concave, reveals 
synergism between GA and CQ.
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Rapid inhibition of parasitemia by GA. P. falciparum 3D7 cul-
tures at 5% parasitemia were exposed to the indicated con-
centrations of GA, and subsequent parasitemia were 
measured at different time points thereafter (Materials and 
Methods). Control treatments using the vehicle (DMSO) 
without GA are represented by filled circles.
+
0
5
10
15
20
25
P
a
r
a
s
i
t
e
m
i
a
 
(
%
)
0 20 40 60 80 100
[GA], nM
Incubation time (h)
0
5
10
20
40
80
160Malaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/30
Page 7 of 11
(page number not for citation purposes)
stages of P. falciparum and that the parasites are destroyed
within a single developmental cycle [34].
Discussion
Our in vitro results presented here demonstrate that GA
can function as an effective antimalarial, at least in eryth-
rocytic culture, and that it is effective against chloroquine-
resistant strains as well. The impressive reduction (5–10
fold) of IC50 of both drugs when used together (Fig. 4)
suggests that GA can be used in combination with CQ. As
mentioned before, GA and its derivatives are already FDA-
approved for Phase I clinical trials in cancer patients, par-
ticularly those with advanced solid malignancies of the
breast [11–15]. When treated with 17-(allylamino)-17-
demethoxygeldanamycin (17AAG), derivative of GA,
breast cancer cells were arrested in G1, underwent subse-
quent mammary differentiation, and then apoptosis.
Interestingly, despite the spectrum of important proteins
that are degraded in response to these drugs, they showed
antitumor activity in animals at doses that are not partic-
ularly toxic. In human cancer patients, micromolar peak
concentrations were achieved without significant toxicity,
which suggested a favorable pharmacology [12–14]. Thus,
it appears that GA and 17AAG are worth testing in animal
and human Plasmodium infections.
It is important to note that pairs of antimalarial drugs
interact with various degrees of cooperativity or antago-
nism which must be experimentally determined. For
example, while mefloquine and clotrimazole are synergis-
tic, CQ and clotrimazole are antagonistic [41]. The dem-
onstration that CQ and GA act synergistically (Fig. 4)
makes antimalarial therapy with a combination of these
two drugs a viable option. It is also gratifying to find that
development of CQ-resistance did not simultaneously
lead to a resistance to GA (Fig. 3). Together, these results
reinforce the facts that the CQ-resistant strains do not
cause an efflux of GA and that the target of GA and CQ are
indeed different, i.e., while GA most likely inhibits
Hsp90, the principle target of CQ is the parasitic digestive
vacuole and requires PfCRT, a membrane transporter
[40].
The Hsp90 sequence is highly conserved throughout evo-
lution. The sequence conservation is particularly notable
in the approximately 220 residues at the N-terminus,
which forms the ATP/GA-binding pocket, and the roughly
500 residue long C-terminus, which is mainly involved in
interaction with other proteins such as the cochaperones
[8,9,16,17]. The sequence between these two domains is
variable but generally consists of highly charged (acidic
and basic) amino acid residues. Interestingly, most species
studied to date contain at least two Hsp90 paralogs, and
P. falciparum seems to be no exception. While the PfHsp90
presented in this paper is located on chromosome 7 (Plas-
moDB ID: PF07_0029), P. falciparum has at least one
other Hsp90 paralog, located on chromosome 12 (Plas-
moDB ID: PFL1070c; manuscript in preparation). Fig. 8
shows a multiple alignment of the N-terminal ATP-bind-
ing domain of the two Plasmodium  paralogs and their
comparison with a representative mammalian Hsp90,
namely the major human Hsp90 (P07900). The high
sequence conservation was evident by the fact that the N-
terminal domain of PfHsp90 (Fig. 8) shared a remarkably
high 49% identity with the other paralog and 73% with
the human ortholog. When the full-length sequences were
compared, these numbers were 36% and 60% respec-
tively. The in vitro results of ATP-PfHsp90 interaction (Fig.
2) and its inhibition by GA closely matched those of
Grenert et al [19] who used human Hsp90β in similar
studies. Successful competition for ATP-binding by GA
(Fig. 2) suggests that as with mammalian Hsp90, the P.
falciparum protein also has an ATP-binding pocket where
both GA and ATP compete to bind. Mutagenesis and crys-
tallographic studies have identified a number of amino
acid residues in this pocket important for interaction with
ATP and GA (16, 17). It is notable that all of these
residues, as highlighted in Fig. 8, are conserved in the two
Plasmodium Hsp90 sequences, suggesting that the second
PfHsp90 may have similar ATP-binding activity that may
also be inhibited by GA. As a corollary, the antimalarial
Morphological changes in GA-treated P. falciparum Figure 6
Morphological changes in GA-treated P. falciparum. Asyn-
chronous P. falciparum 3D7 culture was exposed to a range 
of GA concentrations for 48 h, and then thin smears of the 
cultures were made and stained with Giemsa. An equal vol-
ume of DMSO was added in the control cultures ("no GA"). 
A representative population exposed to 40 nM GA is shown. 
Infected erythrocytes containing stained parasites and a few 
stages are indicated with arrowheads (R = ring, T= tropho-
zoite, S = schizont). Note the complete disappearance of 
parasites in the GA-treated culture and the appearance of 
pyknotic bodies (P).
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effect of GA reported here could be due to the inhibition
of either or both Plasmodium Hsp90 homologs. Clearly,
identification of the exact target of GA in Plasmodium must
await studies of expression of the other Hsp90 homologs
of  Plasmodium  and determination of their relative GA
sensitivity.
Besides GA, there are a number of other compounds that
also inhibit Hsp90 and interfere with its chaperone func-
tion. These include members of the ansamycin antibiotic
family, namely herbimycin, and macbecin I and II, which
are structurally similar to GA and bind to the nucleotide-
binding pocket of Hsp90, and coumarin-type antibiotics,
exemplified by novobiocin, originally discovered as an
inhibitor of bacterial DNA gyrase B [42–44]. Radicicol, a
macrocyclic antifungal structurally unrelated to GA, also
specifically binds to and inhibits Hsp90. As expected,
many of these drugs inhibit the ATPase activity of the
Hsp90 complex, and all of them promote proteolytic deg-
radation of Hsp90 client proteins. Based on the high
degree of sequence similarity between PfHsp90 and mam-
malian Hsp90, we predict that all of these compounds
may also act as antimalarials.
There is now mounting evidence, albeit indirect, support-
ing the existence of a highly active protein chaperone
system in Plasmodia. First, our results and previous publi-
cations have led to the characterization of a Plasmodium
ortholog of Hsp90, an ATP-utilizing molecular chaperone
conserved across evolution, and sequence analysis sug-
gested that there might be others (Fig. 8). Consistent with
its greater need in conditions that lead to protein misfold-
ing, PfHsp90 transcript levels increased three to four fold
when erythrocytic parasite culture was shifted from 37°C
to 41°C [24].
Second, as mentioned before, a large variety of important
cell cycle proteins, kinases, and transcription factors
depend on Hsp90 for proper folding and stability [8,9].
Consistent with this task, Hsp90 is known to be essential
in all eukaryotes. The mechanism of Hsp90 action is
complex and many of its aspects are still being elucidated.
In its chaperone cycle, Hsp90 forms transient complexes
with a number of participating proteins that include
Hsp70, Hip (Hsp70 interacting protein), Hop (p60), p23,
and immunophilins [8,9]. The orthologs of all of these
proteins also seem to exist in Plasmodium. Multiple
Hsp70-like genes and a grp78 (glucose-regulated protein),
Effect of GA on stage-specific development of P. falciparum Figure 7
Effect of GA on stage-specific development of P. falciparum. Ring-stage synchronized P. falciparum 3D7 cultures were continu-
ously exposed for 24 h or 48 h with the same concentrations of GA as in Fig. 5, and the stained parasites were morphologically 
characterized as ring (R), trophozoite (T), and schizont (S). The pyknotic changes (P) were also scored at the same time. Num-
bers are average of three experiments with less than 15% variation.
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another stress protein of the same family, have been
described in Plasmodium [45,46]. Like PfHsp90, these pro-
teins are also highly immunogenic, and the transcription
of these genes is elevated upon heat shock. A 58 kDa Plas-
modium protein (called heat shock-related protein, Hrp)
has been identified that has significant similarity to Hip
and contains TPR motifs [47]. A homology search of the
P. falciparum genome sequence also revealed sequences
with significant homology to Hop (chr14_1.gen_156)
and p23 (chr14_1.gen_248) [[48], our unpublished data].
The Plasmodium  Hop and Hsp70 proteins also contain
TPR motifs, and Hsp90 is known to have a propensity to
interact with TPR-domain proteins [8,9]. We have already
shown that PfHsp90 binds to the TPR-phosphatase, PfPP5
[5]. Taken together, these findings not only suggest the
existence of an active chaperone pathway in Plasmodium,
but also point to the possibility that many members of the
pathway are regulated by reversible phosphorylation.
Clearly, further characterization of this process will lead to
important directions in the regulation of parasitic gene
expression.
Folding and stability of proteins are intimately connected:
the vast majority of improperly folded proteins are gener-
ally ligated to ubiquitin and degraded by the proteasome
machinery [49]. Thus, by blocking Hsp90 function, GA
promotes the degradation of the proteins that depend on
Hsp90 for optimal folding [21,22,44]. Recent reports
have, in fact, described a proteasome S4 ATPase homolog
[50] and ubiquitin in P. falciparum [51] and, interestingly,
polyubiquitin expression was regulated during parasite
development and by heat shock. It is thus tempting to
speculate that Plasmodium has an ATP-ubiquitin-proteas-
ome pathway that is functionally similar to higher
eukaryotes and mediates non-lysosomal degradation of
cytosolic proteins of the parasite. Our preliminary results
(not shown) indicated that a specific subset of P. falci-
parum proteins is indeed degraded in GA-treated parasites,
Hsp90 sequence similarity Figure 8
Hsp90 sequence similarity. Only the N-terminal domains of three Hsp90 sequences are shown: PfHsp90 (the P. falciparum 
Hsp90 studied in this paper), PfHsp90-2 (another potential Hsp90 paralog in P. falciparum), and a major Homo sapiens (human) 
Hsp90 (HsHsp90). The total amino acid residues of the full-length sequences are 745, 821, and 732 respectively. Residues 
known to be important for ATP and GA binding are colored red. Details are in the Results.
PfHsp90         ------------------------------------------------------------ 
PfHsp90-2       MKLNNIYSFFFLFFVLCVIQENVRRVLCDSSVEGDKGPSDDVSDSSGEKKEVKRDRDTLE 60 
HsHsp90         -------------------------------------------------------MPEET  5 
PfHsp90         ---------MSTETFAFNADIRQLMSLIINTFYSNKEIFLRELISNASDALDKIRYESIT  51 
PfHsp90-2       EIEEGEKPTESMESHQYQTEVTRLMDIIVNSLYTQKEVFLRELISNAADALEKIRFLSLS 120 
HsHsp90         QTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLT  65 
                          . *:. ::::: :*:.:*:*::*::**:********::***:***: ::: 
PfHsp90         DTQKLSAEPEFFIRIIPDKTNNTLTIEDSGIGMTKNDLINNLGTIARSGTKAFMEAIQ-A 110 
PfHsp90-2       DESVLGEEKKLEIRISANKEKNILSITDTGIGMTKVDLINNLGTIAKSGTSNFLEAISKS 180 
HsHsp90         DPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQ-A 124 
                : . *    :: *.: .:* .. *:* ::****** **:*******:***. *:**:  : 
PfHsp90         SGDISMIGQFGVGFYSAYLVADHVVVISKNNDDEQYVWESAAGGSFTVTKDETNEKLGRG 170 
PfHsp90-2       GGDMSLIGQFGVGFYSAFLVADKVIVYTKNNDDEQYIWESTADAKFTIYKDPRGATLKRG 240 
HsHsp90         GADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTG-EPMGRG 183 
                ..*:*:***********:***: * * :*:****** *** *...**:  *     : ** 
PfHsp90 TKIILHLKEDQLEYLEEKRIKDLVKKHSEFISFPIKLYCERQNEKEITASEEEEGEGEGE 230 
PfHsp90-2 TRISLHLKEDATNLLNDKKLMDLISKYSQFIQFPIYLLHENVYTEEVLADIAKDMVN--- 297 
HsHsp90 TKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAEEK----- 238 
                *:: *:**:*  : *::::: :::.*:*:** :** *  *.   .*:  .  ::Malaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/30
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suggesting that this may make additional contributions to
the antimalarial mechanism of GA.
After our manuscript was submitted, a recent publication
by Banumathy et al [52] came to our attention that
described inhibition of P. falciparum by GA, thus vindicat-
ing the basic conclusion of our paper. Unfortunately,
however, use of different procedures and lack of appropri-
ate controls made evaluation of some of their results dif-
ficult. For example, these authors reported an IC50
(termed LD50) of 200 nM for GA against erythrocytic cul-
tures of P. falciparum 3D7, which is ten-fold higher than
our IC50 value of 20 nM. We believe the difference is due
to the fact that Banumathy et al exposed the parasite cul-
ture to GA for 24 hr only, whereas we exposed for 48 hr.
Initially, we used a 24 hr exposure protocol, and also
obtained an IC50 value of 200 nM; however, under the
same conditions (i.e., 24 hr exposure), CQ exhibited an
IC50 of 250 nM, which is more than ten times the
accepted value in literature [38,39]. Thus, we optimized
the drug exposure time to 48 hr, which resulted in the
IC50 values of 20 nM and 15 nM, respectively for GA and
CQ (Fig. 3). Banumathy et al did not use any known anti-
malarial drug as positive control. These authors also per-
formed density gradient and pull-down experiments to
determine the binding partners of PfHsp90; however, lack
of quantitation and specific detection of the associated
proteins left their identities uncertain. Based solely on
GA's ability to inhibit Plasmodium growth, Banumathy et
al concluded that Hsp90 is essential in the parasitic life
cycle. We believe the conclusion is premature as it is still
unknown whether Hsp90 is the exclusive parasitic target
of GA. Isolation of spontaneous GA-resistant mutants of
P. falciparum and mapping of the mutations to specific
PfHsp90 gene(s), currently in progress in our laboratory,
should shed light on the relative roles and essentiality of
Hsp90 in the parasite.
Conclusion
The heat shock protein 90 (Hsp90) of P. falciparum is
highly similar to its orthologs in other species in both
sequence and biochemical activities that are relevant to its
chaperone function. The inhibitory effect of geldanamy-
cin on the ATP-binding activity of Plasmodium  Hsp90
offers a potential biochemical mechanism for the antipar-
asitic effect of geldanamycin. Further characterization of
the parasitic Hsp90 chaperone pathway and its client pro-
teins may provide important targets for novel antiparasitic
drugs. The relatively low IC50 (20 nM) of GA against Plas-
modium and the substantially higher concentration (in the
micromolar range) achieved in human serum without
overt toxicity make it a potential candidate for further
development as an antimalarial.
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